title: [The results of retreatment of pulmonary tuberculosis using a short 6-month protocol 1985-1991 in the pneumo-phthisiology department of the Point G hospital in Bamako].
abstract: This study concerns 321 files of smear positive tuberculosis patients admitted in the pneumo-phtysiology service of Pt G Hospital for re-treatment from April 1985 to December 1991. The re-treatment pulmonary tuberculosis with positive spits represent 13.3% of pulmonary tuberculosis cases and 10.1% of the whole tuberculosis diseases. High rate with a ratio of 3 men for a woman was found among men. The same conclusion was reached by SAMAKE (7). Patients age raking from 20 to 49 were the most affected in a proportion of 75.7%. Evolutive relapses were the principal reasons for re-treatment (71.2%) and take place above all among patient treated with the 12 months conventional regime. The conclusion reached corroborates those of STYBLO (8). The regime was 3RHZES3/3R3H3E3. The maximum of negating has been reached during the 3rd month with 93.4% rate. It has been during these 3 last months consolidation phase that the highest drop out has been noticed (17.1%). This is certainly due to the better off felt by patients. At the end of treatment 76.3% of the patients have recovered against 1.5% failure rate and 5.3% drop out. Our treatment regime, though different from those advised by WHO and IUATLD, is an efficient one. However in the new programme of fighting against tuberculosis of Mali, it has been decided to replace our treatment with that of WHO and IUATLD.
authors.affiliation: Service de pneumophtisiologie Hôpital Point G Bamako Mali.
authors.forename: D
authors.initials: D
authors.lastname: Kayantao
authors.forename: B
authors.initials: B
authors.lastname: Keïta
authors.forename: S
authors.initials: S
authors.lastname: Sangaré
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008302:Mali; D008875:Middle Aged; D010349:Patient Compliance; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D019233:Retreatment; D012189:Retrospective Studies; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D012737:Sex Factors; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000008:administration & dosage / Q000627:therapeutic use; D013828:Thioacetazone / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology; D014944:World Health Organization
chemical_list: D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D004338:Drug Combinations; D011718:Pyrazinamide; D013828:Thioacetazone; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin